Literature DB >> 12094264

Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry.

J Trka1, M Kalinová, O Hrusák, J Zuna, O Krejcí, J Madzo, P Sedlácek, V Vávra, K Michalová, M Jarosová, J Starý.   

Abstract

The clinical significance of WT1 gene expression at diagnosis and during therapy of AML has not yet been resolved. We analysed WT1 expression at presentation in an unselected group of 47 childhood AML patients using real-time quantitative reverse-transcription PCR. We also showed that within the first 30 h following aspiration RQ-RT-PCR results were not influenced by transportation time. We observed lower levels of WT1 transcript in AML M5 (P = 0.0015); no association was found between expression levels and sex, initial leukocyte count and karyotype-based prognostic groups. There was significant correlation between very low WT1 expression at presentation and excellent outcome (EFS P = 0.0014). Combined analysis of WT1 levels, three-colour flow cytometry residual disease detection and the course of the disease in 222 samples from 28 children with AML showed remarkable correlation. Fourteen patients expressed high WT1 levels at presentation. In eight of them, who suffered relapse or did not reach complete remission, dynamics of WT1 levels clearly correlated with the disease status and residual disease by flow cytometry. We conclude that very low WT1 levels at presentation represent a good prognostic factor and that RQ-RT-PCR-based analysis of WT1 expression is a promising and rapid approach for monitoring of MRD in approximately half of paediatric AML patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12094264     DOI: 10.1038/sj.leu.2402512

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

1.  High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Akira Shimada; Tomohiko Taki; Daisuke Koga; Ken Tabuchi; Akio Tawa; Ryoji Hanada; Masahiro Tsuchida; Keizo Horibe; Ichiro Tsukimoto; Souichi Adachi; Seiji Kojima; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2012-08-23       Impact factor: 2.490

2.  WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Authors:  M-T Krauth; T Alpermann; U Bacher; C Eder; F Dicker; M Ulke; S Kuznia; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-08-11       Impact factor: 11.528

3.  Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases.

Authors:  Caroline Woehlecke; Susan Wittig; Clemens Arndt; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-20       Impact factor: 4.553

4.  Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Authors:  Sébastien Anguille; Ann L Van de Velde; Evelien L Smits; Viggo F Van Tendeloo; Gunnar Juliusson; Nathalie Cools; Griet Nijs; Barbara Stein; Eva Lion; Ann Van Driessche; Irma Vandenbosch; Anke Verlinden; Alain P Gadisseur; Wilfried A Schroyens; Ludo Muylle; Katrien Vermeulen; Marie-Berthe Maes; Kathleen Deiteren; Ronald Malfait; Emma Gostick; Martin Lammens; Marie M Couttenye; Philippe Jorens; Herman Goossens; David A Price; Kristin Ladell; Yoshihiro Oka; Fumihiro Fujiki; Yusuke Oji; Haruo Sugiyama; Zwi N Berneman
Journal:  Blood       Date:  2017-08-22       Impact factor: 22.113

5.  Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.

Authors:  Lili Xiang; Jiahe Zhou; Weiying Gu; Rong Wang; Jiang Wei; Guoqiang Qiu; Jiannong Cen; Xiaobao Xie; Zixing Chen
Journal:  Oncol Lett       Date:  2015-12-23       Impact factor: 2.967

Review 6.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

7.  Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia.

Authors:  Barbara-Ann Guinn; Azim Mohamedali; Ken I Mills; Barbara Czepulkowski; Michael Schmitt; Jochen Greiner
Journal:  Biomark Insights       Date:  2007-02-14

8.  WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group.

Authors:  Suzie A Noronha; Jason E Farrar; Todd A Alonzo; Robert B Gerbing; Norman J Lacayo; Gary V Dahl; Yaddanapudi Ravindranath; Robert J Arceci; David M Loeb
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

9.  Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression.

Authors:  Jaroslav Polák; Hana Hájková; Jacqueline Maalaufová-Soukupová; Jana Marková; Cyril Sálek; Jiří Schwarz; Cedrik Haškovec
Journal:  Exp Ther Med       Date:  2011-10-11       Impact factor: 2.447

Review 10.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.